Li Z, Yin DF, Wang W, Zhang XW, Zhou LJ, Yang J. Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation. World J Clin Cases 2021; 9(32): 9869-9877 [PMID: 34877325 DOI: 10.12998/wjcc.v9.i32.9869]
Corresponding Author of This Article
Dong-Feng Yin, MD, Chief Doctor, Professor, Oncology Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Shenyang 110032, Liaoning Province, China. 148003642@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2021; 9(32): 9869-9877 Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9869
Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation
Zheng Li, Dong-Feng Yin, Wei Wang, Xin-Wei Zhang, Li-Jiang Zhou, Jun Yang
Zheng Li, Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang 110847, Liaoning Province, China
Dong-Feng Yin, Li-Jiang Zhou, Jun Yang, Oncology Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China
Wei Wang, Xin-Wei Zhang, Department of Integrated Traditional Chinese and Western Medicine, Liaoning Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China
Author contributions: Li Z was responsible for study design, collected and analyzed the data, and drafted the manuscript; Wang W collected and analyzed the data and reviewed the manuscript; Zhang XW, Zhou LJ, and Yang J were responsible for date analysis and review of the manuscript; Yin DF was responsible for study co-design, data analysis, and critical review of the manuscript; all authors approved the final version of the manuscript to be submitted.
Institutional review board statement: The study was reviewed and approved by the institutional review board of Liaoning Cancer Hospital and Institute.
Clinical trial registration statement: This study is not registered.
Informed consent statement: All study participants, or their legal guardian, provided written consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest to disclose.
Data sharing statement: There is no additional data available.
CONSORT 2010 statement: The manuscript was checked and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong-Feng Yin, MD, Chief Doctor, Professor, Oncology Department, The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 33 Beiling Street, Shenyang 110032, Liaoning Province, China. 148003642@qq.com
Received: June 22, 2021 Peer-review started: June 22, 2021 First decision: July 5, 2021 Revised: July 16, 2021 Accepted: August 25, 2021 Article in press: August 25, 2021 Published online: November 16, 2021 Processing time: 140 Days and 17.7 Hours
ARTICLE HIGHLIGHTS
Research background
The incidence of colorectal cancer is on the rise. The immune function of patients with colorectal cancer after adjuvant chemoradiotherapy affects their quality of life.
Research motivation
Traditional Chinese medicine (TCM) has demonstrated great potential in improving patients’ clinical symptoms, regulating the immune function, improving the life quality, and reducing the adverse effects (AEs) of chemotherapy.
Research objectives
This study aimed to observe the clinical efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in patients with colorectal cancer after operation.
Research methods
The scores of TCM symptoms, Karnofsky performance scale (KPS) score, levels of T-cell subsets, and AEs after chemotherapy of the two groups were observed.
Research results
Compared with the control group, the experimental group improved significantly in scores of TCM symptoms, KPS score, levels of T-cell subsets, and AEs of chemotherapy.
Research conclusions
Yiqi Jianpi anti-cancer prescription can effectively improve spleen deficiency, regulate the immune function, alleviate the AEs of chemotherapy, and improve the life quality of patients with good therapeutic effects and application prospect in clinical practice.
Research perspectives
Yiqi Jianpi anti-cancer prescription can be further used in clinical practice. It can invigorate qi, promote the spleen, dissipate mass, and detoxify. It can also improve spleen deficiency and the life quality of patients.
